Welcome to our dedicated page for Nano Labs SEC filings (Ticker: NA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nano Labs Ltd (NA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Nano Labs files annual reports on Form 20-F and current reports on Form 6-K, which are used to furnish press releases, unaudited consolidated financial statements, and management’s discussion and analysis of financial condition and results of operations.
Recent Form 6-K filings incorporate by reference a range of documents into Nano Labs’ effective Form F-3 shelf registration statements. These include press releases on Web 3.0 infrastructure initiatives, crypto-asset reserve strategies involving BNB and BTC, share repurchase programs, at-the-market equity offerings, uplisting to the Nasdaq Global Market, and early repayment of convertible bonds. One Form 6-K also furnishes unaudited consolidated financial statements and related MD&A, along with Inline XBRL instance and taxonomy extension documents.
Through these filings, investors can track how Nano Labs describes its role as a Web 3.0 infrastructure and product solution provider, a fabless IC design company focused on HTC and HPC chips, and a participant in the crypto assets space. The filings also document changes to share structure, voting rights, and amendments to its memorandum and articles of association approved at shareholder meetings.
On Stock Titan, Nano Labs filings are updated as they are made available on EDGAR, and AI-powered summaries can help explain the contents of lengthy reports. Users can quickly see which filings relate to capital raising under Form F-3, which provide financial statements and MD&A, and which furnish key press releases that outline strategic directions in computing power and Web 3.0.
Nano Labs Ltd (NASDAQ: NA) filed Prospectus Supplement No. 4 to its May 2 2025 F-1 prospectus to register the potential resale of 652,174 Class A ordinary shares that may be issued upon exercise of outstanding warrants. The supplement incorporates three Form 6-K reports dated 2, 7 and 8 July 2025 and attaches the full warrant agreement, placement documents and Cayman legal opinions.
Key terms
- The warrants were issued in an April 11 2024 private placement and carry an $10.00 exercise price, initial exercise date of June 2025 and five-year term.
- The closing share price on 8 July 2025 was $7.86, below the exercise price, making near-term cash exercise unlikely.
- Exercise may be for cash or, under certain conditions, via cashless exercise. Anti-dilution provisions adjust the exercise price for stock splits, dividends, or dilutive issuances.
- No primary shares are being sold by the company; the selling shareholders will bear selling commissions. Nano Labs would receive proceeds only if warrants are exercised.
- The supplement reiterates high-risk disclosures and incorporates Cayman counsel’s opinion that the shares, when issued, will be validly issued, fully paid and non-assessable.
Investor implications
- Dilution potential: Full exercise would add ~2.3 % to current Class A float (based on ~28 m shares outstanding in last 20-F).
- Limited immediate impact: With the warrants currently out-of-the-money, cash inflow to Nano Labs is uncertain and resale volume depends on future share price performance.
- Legal clarity: Filing provides detailed warrant mechanics, tax opinions and confirms incorporation of recent 6-K disclosures into the registration statement.